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Abstract 
A reversed-phase (RP) high-performance liquid chromatography (HPLC) method for the content 
determination of IR780-oleyl (IRO) dye in lipid nanoparticles was developed and validated. 
Chromatographic separation was performed on a RP C18 column with a gradient program of water 
and acetonitrile both with 0.1% (v/v) TFA, at a flow rate of 1.0 mL/min and a total run of 21 min. 
IRO dye detection was made by fluorescence at emission wavelength of 773 nm (excitation 
wavelength: 744 nm). According to ICH guidelines, the developed method was shown to be 
specific, linear in the range 3-8 µg/mL (R2=0.9998), precise at the intra-day and inter-day levels as 
reflected by the coefficient of variation (CV ≤ 1.98%) at three different concentrations (4, 6 and 
8 µg/mL) and accurate, with recovery rates between 98.2-101.6% and 99.2-100.5%. The detection 
and quantitation limits were 0.41 and 1.24 µg/mL, respectively. Stability studies of sample 
processing showed that IRO dye was stable after 24 h in the autosampler or after three freeze/thaw 
cycles. Combined with fluorescence measurements, the developed method was successfully 
applied to optimize the loading capacity of IRO dye in the core of lipid nanoparticles.  
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1 Introduction 
Throughout the last decade, bioimaging has become an essential modality to gain information on 
biological materials or processes, from subcellular structures to entire multicellular organisms. 
Amongst optical imaging modalities, fluorescence imaging has found particular interest because of 
its non-invasive and non-ionizing radiation limiting side effects, facilitates detection and 
monitoring of disease progression due to repeated observations (Etrych et al., 2016; Gibson et al., 
2005). Many fluorescent dyes are currently employed to label tumors cells; either in vivo (in whole 
animal studies) or in vitro/ex vivo. In the near infrared (NIR) spectral region between 700 and 1000 
nm, organisms and tissues possess low absorption and autofluorescence, thus enhancing deep 
tissue penetration and image sensitivity with limited background interference and photo-damage to 
biological samples. Consequently, fluorescent organic probes within the NIR spectral window can 
be readily detected and distinguished from the surrounding biological environment by 
commercially available imaging systems (Frangioni, 2003; Smith et al., 2009). Therefore, NIR 
fluorescence imaging is an attractive modality for in vivo cancer diagnosis and particularly used at 
the early stage of detection (Biffi et al., 2015; Santra et al., 2005). As an emerging field, many 
organic NIR probes have been designed with chemical structure based on cyanines, squaraine, 
phthalocyanines and porphyrin derivatives, or rhodamine and BODIPY analogues. These organic 
dyes have been prepared using different strategies including targeting activation and chemical 
conjugation; leading to improved chemical and photostability properties, as well as to increased 
fluorescence intensity and fluorescent half-life (Gibbs, 2012; Luo et al., 2011; Yi et al., 2014; 
Yuan et al., 2013). As NIR fluorescent light is suitable for real-time visualization in human 
surgery, different fluorescence imaging devices have become available for clinical studies and 
have been employed in the surgical management of patients (Gioux et al., 2010; Keereweer et al., 
2011). Currently, the limitation of NIR fluorescence-guided surgery imaging is most likely due to 
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the limited availability of fluorophores with regulatory approval for human use (Alander et al., 
2012; Mérian et al., 2012). IndoCyanine Green (ICG) being the only NIR dye which is approved 
by the US FDA (Food and Drug Administration), has been employed clinically in diagnosing 
metastases in a number of malignant conditions including breast, lung, skin and esophageal cancer 
(Hachey et al., 2016; Khullar et al., 2009; Troyan et al., 2009; van der Vorst et al., 2013; van Driel 
et al., 2014). The clinical development of such fluorophores is also hampered by intrinsic 
limitations e.g. poor hydrophilicity, quantum yield or instability in vivo (Achilefu, 2010; 
Frangioni, 2003; Hilderbrand and Weissleder, 2010). Taking into account the advantage of recent 
advances in the development of nanoparticles as drug delivery carriers, fluorescence probes have 
been encapsulated into nanoparticles or nanomaterials with the aim to improve its bioimaging 
applicability (Priem et al., 2015; Wittenberg and Haynes, 2009; Wolfbeis, 2015). This strategy has 
been successfully extended to newly designed NIR probes for tumor imaging and cancer diagnosis 
(Altinoğlu and Adair, 2010; Choi and Frangioni, 2010; He et al., 2010). NIR nanotracers are 
expected to preferentially accumulate into tumors driven by the EPR (Enhanced Permeability and 
Retention) effect allowing lesion localization and guiding surgeons to delineate tumor-free 
margins in intra-operative resection (Gibbs, 2012; Maeda, 2001). NIR nanoprobes, are currently in 
preclinical studies in glioma (Su et al., 2013), head and neck cancer (van Driel et al., 2014).  
The iodide fluorophore IR780 exhibited suitable NIR optical properties with high 
photobrightening (Zhang et al., 2010a) and has been employed in sentinel lymph node “mapping” 
in animal and human studies (Yi et al., 2014; Zhang et al., 2010b). Moreover, IR780 has been used 
to design and deliver novel, multifunctional theranostic agents, via derivatization into micelles and 
its encapsulation into nanoparticles, for use in both imaging and photodynamic/thermal therapy 
(Jiang et al., 2015; Tan et al., 2012; Yuan et al., 2015; Yue et al., 2013).  
Building on long-term development of lipid nanoparticle platform (Delmas et al., 2011; Goutayer 
et al., 2010; Lainé et al., 2014), we have formulated in 2013 a new lipid nanocarrier, loaded with 
modified IR780 dye (LipImage®815) for in vivo imaging. Studies in mice have demonstrated that 
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LipImage®815 displays prolonged circulation within the bloodstream and preferential 
accumulation within tumors; facilitating fluorescent imaging over 22 days after injection (Jacquart 
et al., 2013). The toxicity and biodistribution of LipImage®815 have been rapidly investigated in 
clinical trials (Phase 0/I) on healthy beagle dogs (Sayag et al., 2016). Recently, the potential of this 
agent as an in vivo NIR nanotracer has been evaluated for intraoperative fluorescence imaging in 
the surgical excision of malignant masses in dogs (Cabon et al., 2016). To facilitate potential 
clinical utility and regulatory approval, an extensive characterization of our Lipidot® platform has 
been undertaken with the development and validation of a large panel of analytical and physico-
chemical methods (Varache et al., 2016).  
As part of this work, we sought to develop and validate a High Performance Liquid 
Chromatographic Fluorescence Detection (HPLC-FLD) method for the quantification of IR780-
oleyl (IRO) content in lipid nanoparticles, based on the recommendations of the International 
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use; ICH guidelines Q2(R1)(“ICH guideline Q2(R1) : Validation of Analytical 
Procedures : Text and Methodology,” 2005). Using this HPLC-FLD method, we investigated the 
loading capacity and thus selected an optimal dye concentration of LipImage®815 for use in 
future fluorescence imaging guided-surgery applications.  
2 Materials and methods 
2.1 Materials 
The IR780-oleyl dye (IRO) (purity: 98%) was prepared from reaction of IR780 iodide dye and 
oleylamine reagents, which are both commercially available. This synthesis was performed by 
Eras Labo (Saint-Nazaire-les-Eymes, France). Suppocire NBTM was purchased from Gattefossé 
S.A. (Saint-Priest, France). MyrjTM S40 (PEG 40 stearate, 1980 Da) and Super RefinedTM Soybean 
Oil were obtained from Croda Uniquema (Chocques, France). Lipoid® S75 (soybean lecithin at 
69% of phosphatidylcholine) was provided from Lipoid GmbH (Ludwigshafen, Germany). All 
 5 
these excipients were pharmaceutical grade and used as received for preparing all formulations. 
Acetonitrile (ACN), absolute ethanol (EtOH), absolute methanol (MeOH), trifluoroacetic acid 
(TFA) 99.9% were supplied by Sigma Aldrich (Saint-Quentin-Fallavier, France). All other 
chemicals and reagents were analytical grade and were used without further purification. HPLC-
grade water (specific resistance = 18.2 MΩ.cm) was obtained from a Classic DI MK2 water 
purification system (Elga, UK) and was used in all experiments. Lipid nanoparticles were 
formulated using a VCX750 Ultrasonic processor from Sonics (Newtown, USA) equipped with a 
3 mm-diameter microtip. The balance was an XP105 from Mettler Toledo (Columbus, USA), the 
centrifuge was a Heraeus Pico 17 from Thermo Scientific (Waltham, USA) and the vortex was a 
Reax top from Heidolph (Schwabach, Germany).  
2.2 Equipment and chromatographic conditions 
A Waters Alliance 2695 Separation module equipped with a Waters 2475 fluorescence detector 
(FLD) and a Waters 186001863 column heater was used for IRO dye quantification. 
Chromatographic analysis was achieved on a C18 column (SunfireTM, 5 µm, 250 x 4.6 mm, 100 Å) 
(Waters, USA) at 30°C. Data analysis was acquired and processed using EmpowerTM 2 software. 
A Waters Auto Purification LC/MS system, equipped with a 2545 Binary Gradient Module, a 515 
HPLC pump, a 2767 Sample Manager, a 2998 Photodiode Array (PDA) detector and a 3100 mass 
detector, was used for identifying IRO dye components. LC/MS analysis was conducted using a 
C18 column (Atlantis T3, 5 µm, 250 x 4.6 mm, 100 Å) (Waters, USA) at room temperature. Mass 
spectrometric analysis was carried out in positive ionization electrospray mode with the following 
source conditions: capillary voltage 3.5 kV, cone voltage 35 V, source temperature 150°C, 
desolvation temperature 450°C, desolvation gas flow 900 L/h, and cone gas flow 50 L/h. The mass 
range m/z was fixed in the range 200-1000. Instrument control and data acquisition were 
performed using MassLynx SCN627 4.1 software. The optimized method used a binary gradient 
mobile phase consisting of (A) a mixture of water acidified with 0.1% (v/v) TFA solution and (B) 
a mixture of acetonitrile with 0.1% TFA solution. The gradient was applied as following: 0-5 min 
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from 50 to 98% solvent B; 5-10 min from 98 to 100% solvent B; 10-15 min 100% solvent B; 15-
16 min from 100 to 50% solvent; 16-21 min 50% solvent B. A flow rate of 1 mL/min was used 
with a 20 µL injection volume. The eluted peaks were recorded at excitation and emission 
wavelengths of 744 and 773 nm, respectively. After optimization, the gain and emission unit full 
set of the Waters 2475 detector were respectively fixed at 1000 and 100. Separation conditions for 
LC/MS analysis were directly transferred from the procedure described above and applied without 
any modification.  
2.3 Preparation of stock and standard solutions 
Crude oil of IRO dye (10 mg) was dissolved in 100 mL of EtOH to prepare concentrated stock 
solution containing 100 µg /mL. From this later, one working standard solution (8 µg/mL) was 
obtained by further dilution of the stock solution with ethanol. For the preparation of linearity 
curve, calibration standards (3, 4, 5, 6, and 7 µg/mL) were prepared by further dilution of the 
standard solution at 8 µg/mL with ethanol. 
2.4 Preparation of samples from lipid nanoparticle matrices 
Before quantification, IRO dye has to be extracted from lipid nanoparticles by disintegrating the 
oil in water emulsion template. Typically, 200 µL of acetonitrile and 200 µL of methanol were 
added to 100 µL of dye-loaded lipid nanoparticles at 100 mg/mL of total lipids. The resulting 
mixture was vortexed and centrifuged at 16,200 g for 10 min. The supernatant was then collected 
and filtered through a 0.45-µm filter. Before quantifying the released dye using the developed 
method, the supernatant was diluted with ethanol, to reach suitable concentration in the linear 
range defined for the optimized method. For studying specificity, identical extractions conditions 
were applied to blank lipid nanoparticles (which were not loaded with IRO dye).  
2.5 Method validation 
The chromatographic method was validated in agreement with the ICH guidelines Q2(R1)(“ICH 
guideline Q2(R1) : Validation of Analytical Procedures : Text and Methodology,” 2005) in terms 
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of the following analytical parameters: specificity, linearity, accuracy, precision, range and 
robustness.  
2.5.1 Specificity 
The specificity was performed in order to determine the ability of the analytical method to measure 
the concentration of IRO dye into lipid nanoparticles without interferences due to substances that 
composed the nanoformulation (e.g. excipients included in nanoparticle formulation), buffer media 
or mobile phase components. In this way, specificity was evaluated by comparison of 
representative chromatograms containing possible interfering substances from lipid 
nanoformulations and samples containing IRO dye. The mobile phase signal was obtained by 
injecting an ethanol only blank sample.  
2.5.2 Linearity and range 
To evaluate linearity, calibration curves were prepared and analysed in triplicate. Linearity was 
determined by calculation of a regression linear line from the area vs. concentration plot for six 
standard solutions (3, 4, 5, 6, 7 and 8 µg/mL) using linear least squares methodology, and by 
analysis of the respective response factors (i.e. peak area divided by concentration of each standard 
sample). 
2.5.3 Accuracy and precision 
ICH guidelines recommend accuracy evaluation, using a minimum of nine determinations over a 
minimum of three levels covering the range specified. The accuracy and precision were 
determined over a period of 3 days using individually-prepared replicates (N=6) of quality control 
(QC) samples at three levels (4, 6 and 8 µg/mL), followed by their comparison with the calibration 
curves. The accuracy was expressed by (mean observed concentration/spiked concentration) x 100 
and the precision by the coefficient of variation (CV = (standard deviation/mean) x 100). The 
concentration of each sample was determined using the calibration curve and analysed on the same 
day. QC samples were prepared as following: 100 µL of blank lipid nanoparticles (not loaded with 
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IRO dye) at 100 mg/mL of lipids were mixed with 200 µL of ACN and then 200 µL of IRO dye 
solution (at 40 µg/mL in MeOH) were spiked. The resulting mixtures were shaken and centrifuged 
as previously described above. QC samples at three different levels were obtained by appropriate 
dilution of the collected supernatant by using ethanol. 
2.5.4 Detection and quantification limits 
Limit of detection (LOD) and limit of quantification (LOQ) were calculated according to the 
following equations: 
��� = 3.3��  
��� = ͳͲ��  
where σ = standard deviation of the response, S = the slope of the calibration curve. σ and S were 
determined for a specific calibration curve obtained by analysing eight dye solutions from 0.1033 
to 6.198 µg/mL.  
2.5.5 Stability 
Autosampler stability of IRO dye samples was assessed by maintaining the QC samples in the 
autosampler tray of the HPLC instrument for 24 h at room temperature (RT), protected from the 
light. Refresh-RT stability of the samples was obtained over three refresh-RT cycles, by thawing at 
RT for 2 h and refreshing (4°C) for 20 h. For each concentration and each storage condition, six 
replicates were analysed in one analytical batch. The stability of the compound was presented as 
the recovery (%) relative to the freshly prepared samples by comparing the peak area.  
2.6 Preparation of dye-loaded lipid nanoparticles (LipImage® formulations) 
2.6.1 Manufacturing of dye-loaded nanoparticles 
LipImage®815 formulations were prepared according to our previous reported method (Delmas et 
al., 2011; Gravier et al., 2011; Jacquart et al., 2013). Briefly, an oil premix was prepared including, 
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respectively, 85, 255, and 65 mg of Soybean oil, Suppocire NCTM, and Lipoid S75. In order to 
optimize the formulation, different amounts of dye (50, 100, 200, 400, 600, 800, and 1000 µL) 
dissolved in ethanol (10 mg/mL) were poured were into the lipid phase. As wax is in solid phase 
up to 35°C, the complete homogenization of oily phase has been carried out at liquid state by 
gently heating at 40°C without exceeding 50°C to avoid dye degradation. After complete 
evaporation of the solvent under argon flow, the continuous phase, composed of 345 mg of 
MyrjTM S40, and of the appropriate amount of aqueous medium (154 mM NaCl if not stated 
otherwise, qsp 2 mL) was introduced. The vial was then placed in a 20°C water bath and 
sonication cycles were performed during 20 min with intervals of 10 s “Pulse On” and 30 s “Pulse 
Off”. Following filtration of the suspension (200 mg/mL of lipids) through a 5-µm cellulose 
Millipore membrane, purification was carried out overnight using dialysis (154 mM NaCl, 
MWCO: 12-14,000 Da, Spectra/Por®). Lipid nanoparticles were finally formulated at a theoretical 
total concentration of lipids of 100 mg/mL and then filtered through a 0.22-µm cellulose Millipore 
membrane for sterilization before characterization. Free-IRO dye nanoparticles were prepared by 
omitting dye loading. Characterizations of the nanoparticles were performed immediately. Sample 
preparations were performed in triplicate for each IRO dye concentration.  
2.6.2 Particle size and size distribution 
The hydrodynamic diameter of the particles was measured by Dynamic Light Scattering (DLS) at 
173° angle using a Malvern Nano ZS instrument (Zeta Siser Nano ZS, Malvern Instruments, UK) 
equipped with a 4 mW He-Ne laser (λ = 532 nm). Lipid nanoparticle samples were diluted to 
2 mg/mL of lipids in aqueous buffer (15.4 mM NaCl) and poured in Zeta Size Nano cells (Malvern 
Instruments) before each measurement, performed in triplicate. The mean particle size (Z-average 
diameter) was obtained from a fit of a single exponential to the correlation function with the 
corresponding polydispersity index (PDI). The plotted data represent mean values of N=3 
independent measurements.  
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2.6.3 Determination of dye-loading and encapsulation efficiency 
IRO dye content of nanoparticles was assessed after disintegration of the nanoparticles followed 
by collection and quantification of the supernatants obtained after centrifugation, as described in 
the sample preparation section. Each sample was prepared and analysed in duplicate. For each 
series of measurements, an IRO dye solution at 7.7 µg/mL was analysed to calculate the 
concentration of the unknown samples (the amount of entrapped dye). The number of dyes per 
nanoparticles and the local dye concentration were calculated by considering a particle diameter of 
50 nm and a lipid density of 1.05 g/cm3. Entrapment efficacy (EE) and dye loading (DL) were 
determined according to the following equations:  
���������� ���������� ሺ�/�ሻ =  ����ℎ� �� ������ �������ℎ� �� ��������� ����� ��� x 100 
��� ������� ሺ�/�ሻ =  ����ℎ� �� ������ �������ℎ� �� ������ ��� + ����ℎ� �� ������������� x 100 
2.6.4 Photophysical properties 
The absorbance measurements were performed in saline buffer (154 mM NaCl) using a Cary 300 
Scan UV-Visible spectrophotometer (Varian, Les Ulis, France). The absorbance was measured at a 
total dye concentration of 0.456 µg/mL. Fluorescence intensities of the dilute samples were 
measured in duplicate using a microplate reader (TECAN Infinite M1000) at excitation and 
emission wavelengths of 793 and 814 nm, respectively. Results were expressed as the normalized 
fluorescence intensity (fluorescence intensity x (1-10-0.1)/(1-10-absorbance)) where the absorbance was 
determined for each sample at the maximum absorption wavelength, i.e. λ = 793 nm. Data 
normalization compensated for inhomogeneities within the samples, laser power fluctuations 
between measurements or coupling variations.  
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3 Results & Discussion 
3.1 Development of the analytical method 
3.1.1 Selection of an HPLC method with fluorescence detection 
This is the first study to describe a simple, precise and accurate HPLC method coupled with 
fluorescence detection for the assessment of IRO dye derivatives encapsulated into nanomaterials 
(Fig. 1). The conventional method for quantitating IR780-iodide loaded into nanoparticles is by 
absorbance spectrophotometry at 780-800 nm after disruption of the nanosystems (Chen et al., 
2016; Li et al., 2016; Pais-Silva et al., 2017; Peng et al., 2011). Whilst simple and rapid, it suffers 
from obvious low assay sensitivity. Furthermore, this assay is not specific, and quantitation of 
IR780-iodide by this method relies on the assumption that the dye is neither degraded nor 
transformed prior to analysis. Detection based on fluorescence modality should increase 
sensitivity, thus allowing precise quantification after administration in the whole-body volume and 
limiting the amount of sample required for this purpose. Furthermore, a quantitative method which 
meets the regulatory requirements is crucial to ensure the industrial transfer of our nanomedicine 
product. According to ICH guidelines and FDA guidance documents, a stability-indicating method 
must be chosen excluding UV-visible spectrophotometric assays (FDA, 2001, 2000; “ICH 
guideline Q2(R1) : Validation of Analytical Procedures : Text and Methodology,” 2005). A 
stability-indicating method accurately measures variations within the active ingredients 
concentration, without interference from the others degradation products, impurities and 
excipients. HPLC is most widely used as analytical tool for the separation and quantification of the 
active pharmaceutical ingredients and their related substances. We, therefore, focused on FLD and 
HPLC for the development of our analytical method. 
3.1.2 Sample preparation 
When LipImage®815 formulation was initially developed, the content of the lipophilic-modified 
IR780, loaded into the core of the nanoparticles, was directly determined by measuring absorbance 
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values of particle suspension (Jacquart et al., 2013). As cyanine dyes, IRO dye exhibits lipophilic 
character fostering encapsulation or dissolution into fatty media (Gravier et al., 2011; Jacquart et 
al., 2013). Even if the loading of IRO dye into the core of the nanocarriers does not modify its 
optical properties, its quantification by HPLC relies on the detection of the individual species 
itself, regardless of all the excipients. Consequently, disintegration of dye-loaded nanoparticles 
followed by extraction of IRO dye from lipid matrices has been applied to release dye as free 
substance. This step was previously implemented by Guillot and co-workers (Guillot et al., 2015) 
for Cyclosporine A and was slightly modified for NIR dyes by adapting solvent nature and 
proportions. Considering the oil/water emulsion of lipid nanoparticles, methods involving hydro-
organic solvents would destabilize the interface of droplets providing release of encapsulated 
entities and allowing surfactants to be solubilized. As IRO dye is highly soluble in MeOH, a 
disintegration step consists of mixing the nanoparticles with four volumes of ACN/MeOH:50/50 
(v/v). Then, the supernatant is carefully collected and filtered after centrifugation. Before 
quantifying the released dye using the developed method, the supernatant is diluted with ethanol in 
order to reach suitable concentration in the linear range defined for the optimized method. Opaque 
containers or covering with aluminium foil was also employed to minimize light exposure. 
3.1.3 Near infrared IRO dye derivatives as substances to be quantified 
IR780-iodide dye and its derivatives have demonstrated suitable optical properties for in vivo 
bioimaging in the specific 700- 1000 nm wavelength window (Yuan et al., 2015; Zhang et al., 
2010a, 2010b). To overcome the limitations of most of NIR dyes when injected in their free form 
in aqueous buffers (poor solubility, aggregations and strong adsorption on plasma proteins), novel 
nanoparticles have been employed as carriers (Pais-Silva et al., 2017). To facilitate efficient and 
prolonged encapsulation in the core of lipid nanoparticles, commercially available IR780-iodide 
dye has been derivatizated with an oleyl chain (C18 alkyl chain), enhancing its lipophilic 
character, to provide IR 780-Oleyl (IRO). The lipid nanoparticles encapsulating IRO dyes were 
annotated LipImage®815 as nanomedicine dedicated to in vivo imaging diagnosis (Jacquart et al., 
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2013). The enhanced lipophilicity of IRO dye aims to foster a more deeply anchoring of dye into 
the core lipid of nanoparticle, preventing thereby its potential and prematurely escape outside the 
nanoparticles in the bloodstream before reaching tumor sites. The in vivo biodistribution pattern of 
IRO dye is modified by its encapsulation into nanoparticles. Free IRO is largely spread into liver 
and spleen organs after injection whereas a more homogeneous distribution in mice body is 
achieved for encapsulated IRO dye as well as a prolonged circulation in plasma (Jacquart et al., 
2013). The IRO dye (Fig. 1(b)) was synthetized from a two-step chemical modification, as 
previously described (Jacquart et al., 2013). Initially, a carboxylic acid group was introduced in the 
fluorophore template. An oleyl chain was then grafted onto the dye using standard –CO2H/NH2 
coupling chemistry, activated by (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium 
hexafluorophosphate (BOP) and the addition of oleylamine. The solution of oleylamine reagent 
used for manufacturing desired IRO dye contained other amines with long fatty chains. Without 
prior separation of these amine analogues, substitution of chlorine groups of IR780 iodide 
molecules could occur in a same pattern as oleylamine. This finding has been evidenced by 
LC/MS analysis of manufactured IRO dye batch. MS chromatogram (total ion count, TIC) 
revealed a major peak (data not shown) with a molecular ion peak at m/z = 858.9 that can be 
assigned to the IRO dye with oleyl (C18:1) chain. MS chromatogram also showed two minor 
peaks with molecular ion peaks at m/z = 856.9 and 860.9 that can be attributed to the IR780 iodide 
dye with stearyl (C18:0) or linoleyl (C18:2) chains as lipid anchors. Under the selected HPLC-
FLD conditions, the chromatogram of IRO dye batch (Fig. 2) shows three closed peaks: one major 
at 7.94 ± 0.01 min and two minors at 7.81 ± 0.01 and 8.06 ± 0.01 min, respectively. After peak 
integration processed between 7.5 and 8.3 min, these minor peaks represent (6.2 ± 0.2)% and 
(18.4 ± 0.2)% of the total peak area, while the major peak corresponds to (73.6 ± 0.2)%. Content 
of unwanted impurities are estimated to represent less than 2% of the total IRO dye batch. 
Considering low structural differentiation and similar lipophilic character of these C18-anchoring 
IR780 analogues, preparative separation technique cannot be applied due to obvious time-, 
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solvent- and dye-consuming considerations. Regarding optical properties in the NIR window, no 
significant modification would be anticipated, with such similar lipid anchoring. Consequently, 
IRO dye batch including three characterised C18-anchoring IR780 dyes was loaded to design 
LipImage®815 as nanoimaging agent. Integration of chromatograms was assessed between 7.5 
and 8.3 min in order to take into account all the C18-anchoring IR780 analogues.  
3.1.4 Method development and optimization 
Because our modified IR780-iodide dye (IRO) possesses a high lipophilic character evidenced by 
log P = 12, and consequently high solubility in organic systems, chromatographic separation was 
performed on a RP18 column, and a binary gradient elution mobile phase consisting of: (A) a 
mixture of water acidified with 0.1% (v/v) TFA solution, and (B) a mixture of acetonitrile with 
0.1% TFA solution was used. The lowest initial amount of solvent A (aqueous solvent) was found 
to be equal to 50% in order to prevent elution of the dye in the void volume of the column. 
Noticeable tailing and irregular shaping of IRO dye peaks were observed in isocratic mode 
whatever the proportions of the mobile phases. Poor and variable tailing factor values would have 
compromised the accuracy and precision of the method. Temperature was observed to not affect 
the elution and analysis was operated at 30°C to provide reproducibility. TFA solvent was used to 
avoid fluorescence instability due to pH variations. The excitation and emission wavelengths have 
been optimized by using the 3D scan mode in Empower. Finally, the detector was set to excite at 
744 nm and measure the emission at 773 nm. Optimization of the gain and emission unit full set 
(EUFS) of the Waters 2475 detector was performed by the auto-optimizing gain and EUFS 
provided in the Empower software after which minor manual adjustments were made. Then the 
gain was fixed to 1000 whereas EUFS was levelled off at 100. As recommended by ICH 
guidelines, the system suitability was assessed by six replicate analyses of the dye at a 
concentration of 7.7 µg/mL. The %CV of peak area and retention time for IRO was found to be 
less than 1% (0.88% and 0.24%, respectively) indicating the suitability of the system. Under the 
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optimized conditions, the asymmetry factor for the major peak was reached 1.24 ± 0.09 
(mean ± SD), which is acceptable value indicating good symmetry of the method.  
3.2 Method validation  
In our course of extensive characterization for industrial transfer, we have set out to investigate the 
validation of the proposed analytical HPLC-FLD method in order to prove its acceptability for 
intended IRO dye quantification. As recommended by the ICH guidelines (“ICH guideline 
Q2(R1) : Validation of Analytical Procedures : Text and Methodology,” 2005), this validation 
included various studies such as specificity, linearity, precision and accuracy over three days, and 
stability.  
3.2.1 Specificity 
Specificity of the method was evaluated by comparing the chromatograms of IRO dyes with those 
of potential interfering formulation components. Supernatant of empty nanoparticles collected 
from the sample preparation protocol and a blank sample (ethanol) were analysed according to the 
proposed method and compared with the chromatogram of IRO dye containing samples (Fig. 3). 
The representative chromatograms of lipid nanoparticles containing IRO dye (C) and IRO dye 
solution (D), both with similar retention times, showed in both cases no interfering peaks. 
Additionally, no other peaks corresponding to any of the remaining components of the 
nanoparticle formulation or solvent can be observed in the chromatograms of blank nanoparticles 
(A) and the mobile phase (B). These data demonstrated the high specificity of the developed 
method. 
3.2.2 Linearity 
 Linearity is defined as an interval in the measurement range of analytical method in which an 
output signal correlates linearly with the determined analyte concentration. For IRO dye, linearity 
was studied in the concentration range of 3-8 µg/mL by visual inspection of a calibration curve 
(Fig. 4(a)) and by calculating the regression equation and the correlation coefficient (R2) by the 
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method of least squares. The slope and intercept were 12,199 ± 350 and 5,459 ± 1929, 
respectively. The correlation coefficient was 0.9998 ± 0.0004. The results indicate that good 
linearity was observed from 3.0 to 8.0 µg/mL since the regression coefficient R2 > 0.998 is 
generally considered as evidence of acceptable fit of the data to the regression line (Shabir, 2003; 
Shabir et al., 2007). This suitable range was also demonstrated by plotting the relative responses 
(response factors) on Y-axis and the corresponding log concentrations on X-axis (Fig. 4(b)). 
Relative responses are in the range of 95% and 105% of the average value, thus reinforcing the 
evaluation of the method as linear (Sonnergaard, 2006). Poor linearity was observed while 
increasing the concentration until 16 µg/mL.  
3.2.3 Detection and quantification limits 
The lowest concentration at which an analyte can be detected (LOD) or quantified (LOQ) with 
acceptable precision and accuracy can be determined by different methodologies. In our study, 
these parameters have been calculated from the SD of the response and slope of a specific 
calibration curve obtained by injecting in triplicate 8 standards (concentrations from 0.1033 to 
6.198 µg/mL). The calculated LOD of IRO dye was 0.41 µg/mL and the LOQ was 1.24 µg/mL. 
Although the analysis of the R2 (0.998) determined by the method of least squares indicates an 
acceptable linearity, the study of the linear regression for the response factor at concentration 
levels between 0.1033 and 6.198 µg/mL (specific calibration curve) indicated poor linearity (linear 
regression slope: -759.48; RSD: 13.39%). It thus demonstrates that the correlation coefficient is 
not a true measure of linearity and should be reinforced by other linearity assessment method 
(Sonnergaard, 2006). 
3.2.4 Accuracy and precision 
Accuracy is defined by International Organization for Standardization (ISO) as “closeness of 
agreement between a measured quantity value and a true quantity value of a measurand”. Precision 
expresses closeness of agreement between a series of measurements from multiple sampling of the 
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same homogeneous sample under the prescribed conditions (“ICH guideline Q2(R1) : Validation 
of Analytical Procedures : Text and Methodology,” 2005). Accuracy and precision were calculated 
at three concentration levels (4, 6 and 8 µg/mL) (Table 1). The intra-day and inter-day precision 
CV% was <2% at any concentration levels, thus indicating that the proposed method presents 
good precision. The intra-day and inter-day accuracy ranged between 98.2% and 101.6%, and 
between 99.2% and 100.5% (Table 1), thus showing strong agreement between experimental and 
theoretical values. According to FDA guidelines, accuracy should be 100 ± 2% and precision 
should not exceed 2% of the CV (G. Shabir, 2004; G. A. Shabir, 2004; Shabir et al., 2007). This 
analytical method was thus proved to be precise and accurate.  
3.2.5 Stability 
Stability studies of IRO dye samples indicated that the QC samples were stable in the auto-sampler 
for 24 h and after 1 or 3 cycles of refreshing-thawing since the recovery (%) relative to the freshly 
prepared samples are within the acceptance range of 90-110% (Kumar et al., 2014) (Table 2).  
3.3 Applicability of the validated HPLC-FLD method: optimization of LipImage®815 
formulation 
As a nano-contrast agent, LipImage®815 has been designed for imaging purposes based on optical 
properties of entrapped dyes. For drug delivery purposes, the drug loading has to be as high as 
possible (typically 8-10% (w/w) up to 30% (w/w)) in order to deliver to the biological site a 
maximal dose of active molecules with lowest number of nanomaterials. For imaging, the NIR dye 
payload can be as low as 0.02 to 2.5 % (w/w). In our previous work, IRO dye was encapsulated in 
the core of the nanoparticles with a range between 0.07 and 0.7% (w/w) (Jacquart et al., 2013). In 
the present work, the dye payload was extended up to 1.3 % (w/w) in order to optimize 
LipImage®815 formulation. For each dye payload, three samples were formulated and then 
purified separately until the final product was obtained (at a lipid concentration of 100 mg/mL). 
For each sample, the concentration of IRO dye ([Dye]exp) was determined using HPLC. Based on 
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these concentrations, the encapsulation efficiency (EE), the experimental dye loading (DLexp) and 
the number of dyes per nanoparticle (Dyes/NPexp) have been calculated by considering a particle 
diameter of 50 nm and a lipid density of 1.05 g/cm3 (Table 3). By plotting the theoretical dye 
loading (DLtheo) versus the experimental dye loading (DLexp), we are able to show the entrapment 
evolution over the selected range of dye loading (Fig. 5). As previously observed (Jacquart et al., 
2013), loading of the IRO dye in the core of the nanoparticle is highly efficient (80 < EE < 90 %) 
even with the highest number of dyes per nanoparticle (>85% yield, up to 476 dyes/nanoparticle). 
As previously observed for other cyanine dyes, the presence of the alkyl C18 lipophilic chains on 
its structure ensures encapsulation into the lipid core (Gravier et al., 2011). Although EE values 
are high, they pointed out a loss of raw materials (~15-20%), which occurs during the 
nanoparticles manufacturing. Unfortunately, analytical methods for lipid quantification are not yet 
developed and validated to investigate raw material loss. However, using the developed HPLC 
method, we attempted to identify the limiting steps resulting in loss of dye as raw materials. The 
nanoparticles are produced through three main steps: i) preparation of aqueous and oily phases 
including loading of dye, ii) formulation of lipid nanoparticles by emulsification using 
ultrasonication, iii) purification of nanoparticles using dialysis technique. Before dialysis, 
nanoparticle suspensions are filtered through a 5-µm cellulose membrane to remove large 
aggregates such as excipients (soybean oil and wax) which are not included in the nanoparticle 
formulation. Using our validated method, the concentrations of IRO dye for two suspensions with 
DLtheo of 0.79% (w/w) were measured before and after the 5-µm filtration step. We determined 
that EE decreased from (99.4 ± 2.2)% to (94.6 ± 1.0)% with the 5-µm filtration (data not shown). 
Consequently, the filtration step before dialysis removes dye, which has been solubilised in the 
fatty media (soybean and wax) but not integrated in the particle formulation. It was also, however, 
evident that filtration performed after dialysis (through a 0.22-µm cellulose membrane to ensure 
sterility) does not remove dye. Indeed, EE remained almost constant (not shown) after this 
filtration step (EE = 94.9 ± 2.1% before and 94.2 ± 2.0% after filtration). Diffusion Light 
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Scattering (DLS) was also used to assess LipImage®815 hydrodynamic diameter and 
polydispersity index. As previously demonstrated on a narrower range of dye loading (Jacquart et 
al., 2013), both hydrodynamic diameter (Z-average diameter) and polydispersity index (PDI) were 
unaffected by dye loading (Fig. 6). For in vivo imaging applications, fluorescence intensity has to 
be as high as possible while the amount of nanomaterials as low as possible. Also, the dye loading 
can also affect the fluorescence intensity due to the nano-confinement. For this reason, we have 
studied the fluorescence intensity of the suspensions as a function of dye loading. In order to 
minimise re-absorption effects in the fluorescence measurements, the total IRO dye concentration 
of each sample was adjusted (to provide absorbance values <0.1 at the excitation wavelength) 
(Dhami et al., 1995). Above this level, non-linear effects may be observed due to inner filter 
effects, and thereby the resulting fluorescence intensity may be perturbed. Thanks to the 
concentration of IRO dye ([Dye]exp) determined using our validated HPLC-FLD method, each 
sample was suitably diluted with buffer saline solution (154 mM NaCl) until a final dye 
concentration of 0.456 µg/mL, limiting high concentration effect, as checked by absorbance values 
measured below 0.1. Normalized fluorescence intensity has been plotted against the number of 
IRO dyes per nanoparticle (Fig. 7). Normalized fluorescence intensity linearly decreases as a 
function of the experimental number of dyes entrapped in the nanoparticle core. This may be 
explained by the well-known self-quenching caused by the dye proximity when dye loading 
increased, leading to energy transfer between dyes (Shimizu et al., 2014; West and Pearce, 1965; 
Zhegalova et al., 2014). The normalized fluorescence intensity has been also expressed in function 
of the lipid concentration (i.e. the number of particles) after diluting the samples to reach an IRO 
dye concentration of 0.456 µg/mL (Fig. 8). Above 91 dyes/particle (when the number of particles 
decreases), the normalized fluorescence intensity drastically decreases while the dye loading 
increased. Fluorescence intensity remains almost constant below 91 dyes/particle even if the dye 
loading decreases (the number of particles increases). This supports the work of Gravier and co-
workers (Gravier et al., 2011), who demonstrated for 50 nm sized lipid nanoparticles loaded with 
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DiD that the self-quenching value appears when internal concentration reaches above 200 
dyes/particle. Within the range of internal concentration between 22 and 91 dyes/particle, we thus 
possess nanoparticle suspensions with similar fluorescence properties which differ in nanoparticle 
concentration. A sample is either composed of 22 dyes/particle with a large number of 
nanoparticles ([Lipids] = 800 µg/mL) or 91 dyes/particle with a lower amount of nanoparticles 
([Lipids] = 210 µg/mL). As lipid nanoparticles are considered as carriers without imaging ability, 
the lowest amount is injected in the body, the best safety is expected (or the undesired effects are 
limited). Then, the formulation composed of 91 dyes/particle was selected for further preclinical 
studies (Cabon et al., 2016; Sayag et al., 2016).  
4 Conclusion 
We have developed a simple, accurate and validated reversed-phase HPLC-FLD method for the 
quantification of IR780-oleyl content in lipid nanoparticles according to ICH guidelines. This 
method is particularly relevant since the quantification of NIR dyes traditionally is undertaken via 
absorbance, which may be affected by impurities, degradation and/or biotransformation products. 
This HPLC-FLD method is currently useful for the routine dye analysis at laboratory scale and 
could be easily applied with slight modifications to the quantification of other NIR dyes such as 
lipophilic DiD, DiO, DiI cyanine dyes for developing new NIR nanoproducts. Meeting regulatory 
requirements, this fast and simple method could be used for In Process Control (IPC) strategy to 
estimate variations of IRO dye concentrations, which can occur during the manufacturing process 
of LipImage®815. This HPLC-FLD method represents a starting point to design a complete 
analytical method for the analysis of biological samples during clinical evaluation. 
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Figures caption  
Figure 1: LipImage®815 schematic representation. (a) LipImage are dye-loaded oily droplets 
dispersed in buffer solution (NaCl, 154 mM). Their fluorescent properties are conferred by IRO 
dye (b), encapsulated in the lipid core and/or the surfactant layer.  
 
Figure 2: Representative chromatogram between 7 and 9 min of IRO dye solution (8 µg/mL).  
 
Figure 3: Representative chromatograms corresponding to (A) blank lipid nanoparticles, (B) 
mobile phase signal, (C) IRO-loaded lipid nanoparticles, and (D) IRO dye solution (8 µg/mL). 
Chromatograms are presented between a) 0 – 21 min and b) 7 – 9 min. 
 
Figure 4: Linearity studies for the proposed HPLC method: (a) calibration curve obtained with 
IRO dye solutions (n=18 per days), and (b) relative responses (response factors) versus IRO 
concentration. Data are mean of calibration curve performed on three consecutive days.  
 
Figure 5: Encapsulation range of the IRO dye into nanoparticles. 
 
Figure 6: Mean hydrodynamic diameter (Z-average diameter) and Polydispersity index (PDI) 
obtained for selected encapsulation range of IRO dye. Results are expressed as average and SD of 
three independent samples analysed in triplicate. 
 
Figure 7: Normalized fluorescence intensity against the number of IRO molecules per 
nanoparticle. For each sample, IRO dye concentration was adjusted at 0.456 µg/mL.  
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Figure 8: Normalized fluorescence intensity against the lipid concentration. For each sample, IRO 
dye concentration was adjusted at 0.456 µg/mL.  
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Tables 
Table 1: Intra- and inter-day accuracy and precision of HPLC-FLD assay for IRO dye. Spiked 
recovery method was used for accuracy. 
  Accuracy and precision of QC samples 
  Day 1  (n=6) Day 2 (n=6)  Day 3 (n=6) Overall (n=18) 
4.0 µg/mL Mean 4.06 3.95 3.98 3.99 
 S.D. 0.08 0.07 0.08 0.08 
 CV (%) 1.98 1.66 1.91 1.95 
 Recovery (%) 101.5 98.8 99.5 99.9 
 
6.0 µg/mL Mean 6.09 6.07 5.92 6.03 
 S.D. 0.05 0.06 0.08 0.10 
 CV (%) 0.80 0.99 1.53 1.72 
 Recovery (%) 101.6 101.3 98.6 100.5 
 
8.0 µg/mL Mean 7.95 8.01 7.86 7.94 
 S.D. 0.10 0.13 0.12 0.12 
 CV (%) 1.27 1.66 1.59 1.53 
 Recovery (%) 99.3 100.1 98.2 99.2 
 
 
Table 2: Stability of IRO dye QC samples determined with replicates (n = 6) for each 
concentration. aStability in the autosampler was performed at room temperature, bone cycle of 
refreshing-thawing, cthree cycles of refreshing-thawing 
Nominal 24 h in the Post- Post-
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concentration 
(µg/mL) 
autosamplera 
(%) 
preparation 1 
cycleb (%) 
preparation 3 
cyclesc (%) 
4.0 101.4 ± 4.3 101.4 ± 2.4 100.7 ± 3.3 
6.0 100.8 ± 3.2 100.7 ± 3.4 99.8 ± 2.1 
8.0 99.9.4 ± 3.5 100.7 ± 3.1 100.5 ± 2.4 
 
Table 3: Concentration of IRO dye for a concentration of lipids at 100 mg/mL, number of dyes per 
nanoparticle (NP), dye loading (DL) and entrapment efficiency (EE). For each concentration, 
results are expressed as average and SD of three independent samples analysed in duplicate. The 
number of IRO dyes per nanoparticle was calculated from the concentration of dye measured on 
the final product and by considering a particle diameter of 50 nm and a lipid density of 1.05 g/cm3. 
[Dye]theo 
(µg/mL) 
DLtheo (%) 
 [Dye]exp 
(µg/mL) 
DLexp (%) EE (%) Dyes/NPexp 
67 0.07 52.5 ± 6.4 0.052 ± 0.006 78.6 ± 9.4 22.0 ± 2.7 
133 0.13 108.1 ± 4.1 0.108 ± 0.004 81.0 ± 2.9 45.4 ± 1.7 
267 0.27 217.8 ± 10.9 0.217 ± 0.011 81.7 ± 4.0 91.4 ± 4.6 
533 0.53 436.5 ± 50.5 0.43 ± 0.050 82.1 ± 9.6 183.2 ± 21.2 
798 0.79 728.8 ± 16.2 0.723 ± 0.016 91.6 ± 1.9 305.8 ± 6.8 
1,060 1.04 925.1 ± 66.1 0.855 ± 0.108 87.3 ± 6.1 362.5 ± 45.7 
1,322 1.31 1,133.4 ± 20.5 1.119 ± 0.020 85.5 ± 1.6 475.6 ± 8.6 
 
References 
Achilefu, S., 2010. The Insatiable Quest for Near Infrared Fluorescent Probes for Molecular 
Imaging. Angew. Chem. Int. Ed Engl. 49, 9816–9818. doi:10.1002/anie.201005684 
Alander, J.T., Kaartinen, I., Laakso, A., Pätilä, T., Spillmann, T., Tuchin, V.V., Venermo, M., 
 25 
Välisuo, P., 2012. A review of indocyanine green fluorescent imaging in surgery. Int. J. 
Biomed. Imaging 2012, 940585. doi:10.1155/2012/940585 
Altinoğlu, E.I., Adair, J.H., 2010. Near infrared imaging with nanoparticles. Wiley Interdiscip. 
Rev. Nanomed. Nanobiotechnol. 2, 461–477. doi:10.1002/wnan.77 
Biffi, S., Voltan, R., Rampazzo, E., Prodi, L., Zauli, G., Secchiero, P., 2015. Applications of 
nanoparticles in cancer medicine and beyond: optical and multimodal in vivo imaging, tissue 
targeting and drug delivery. Expert Opin. Drug Deliv. 12, 1837–1849. 
doi:10.1517/17425247.2015.1071791 
Cabon, Q., Sayag, D., Texier, I., Navarro, F., Boisgard, R., Virieux-Watrelot, D., Ponce, F., 
Carozzo, C., 2016. Evaluation of intraoperative fluorescence imaging-guided surgery in 
cancer-bearing dogs: A prospective proof-of-concept phase II study in 9 cases. Transl. Res. 
170, 73–88. doi:10.1016/j.trsl.2015.12.001 
Chen, Y., Li, Z., Wang, H., Wang, Y., Han, H., Jin, Q., Ji, J., 2016. IR-780 Loaded Phospholipid 
Mimicking Homopolymeric Micelles for Near-IR Imaging and Photothermal Therapy of 
Pancreatic Cancer. ACS Appl. Mater. Interfaces 8, 6852–6858. doi:10.1021/acsami.6b00251 
Choi, H.S., Frangioni, J.V., 2010. Nanoparticles for biomedical imaging: fundamentals of clinical 
translation. Mol. Imaging 9, 291–310. 
Delmas, T., Couffin, A.-C., Bayle, P.A., de Crécy, F., Neumann, E., Vinet, F., Bardet, M., Bibette, 
J., Texier, I., 2011. Preparation and characterization of highly stable lipid nanoparticles with 
amorphous core of tuneable viscosity. J. Colloid Interface Sci. 360, 471–481. 
doi:10.1016/j.jcis.2011.04.080 
Dhami, S., Mello, A.J.D., Rumbles, G., Bishop, S.M., Phillips, D., Beeby, A., 1995. 
Phthalocyanine Fluorescence at High Concentration: Dimers or Reabsorption Effect? 
Photochem. Photobiol. 61, 341–346. doi:10.1111/j.1751-1097.1995.tb08619.x 
Etrych, T., Lucas, H., Janoušková, O., Chytil, P., Mueller, T., Mäder, K., 2016. Fluorescence 
optical imaging in anticancer drug delivery. J. Controlled Release 226, 168–181. 
doi:10.1016/j.jconrel.2016.02.022 
FDA, 2001. Guidance for Industry: Bioanalytical Method Validation. 
FDA, 2000. Guidance for Industry: Analytical Procedures and Methods Validation. 
Frangioni, J.V., 2003. In vivo near-infrared fluorescence imaging. Curr. Opin. Chem. Biol. 7, 626–
634. 
 26 
Gibbs, S.L., 2012. Near infrared fluorescence for image-guided surgery. Quant. Imaging Med. 
Surg. 2, 177–187. 
Gibson, A.P., Hebden, J.C., Arridge, S.R., 2005. Recent advances in diffuse optical imaging. Phys. 
Med. Biol. 50, R1. doi:10.1088/0031-9155/50/4/R01 
Gioux, S., Choi, H.S., Frangioni, J.V., 2010. Image-guided surgery using invisible near-infrared 
light: fundamentals of clinical translation. Mol. Imaging 9, 237–255. 
Goutayer, M., Dufort, S., Josserand, V., Royère, A., Heinrich, E., Vinet, F., Bibette, J., Coll, J.-L., 
Texier, I., 2010. Tumor targeting of functionalized lipid nanoparticles: Assessment by in vivo 
fluorescence imaging. Eur. J. Pharm. Biopharm. 75, 137–147. doi:10.1016/j.ejpb.2010.02.007 
Gravier, J., Navarro, F.P., Delmas, T., Mittler, F., Couffin, A.-C., Vinet, F., Texier, I., 2011. 
Lipidots: competitive organic alternative to quantum dots for in vivo fluorescence imaging. J. 
Biomed. Opt. 16, 096013. doi:10.1117/1.3625405 
Guillot, A., Couffin, A.-C., Sejean, X., Navarro, F., Limberger, M., Lehr, C.-M., 2015. Solid 
Phase Extraction as an Innovative Separation Method for Measuring Free and Entrapped Drug 
in Lipid Nanoparticles. Pharm. Res. 32, 3999–4009. doi:10.1007/s11095-015-1761-8 
Hachey, K.J., Gilmore, D.M., Armstrong, K.W., Harris, S.E., Hornick, J.L., Colson, Y.L., Wee, 
J.O., 2016. Safety and feasibility of near-infrared image-guided lymphatic mapping of 
regional lymph nodes in esophageal cancer. J. Thorac. Cardiovasc. Surg. 152, 546–554. 
doi:10.1016/j.jtcvs.2016.04.025 
He, X., Gao, J., Gambhir, S.S., Cheng, Z., 2010. Near-infrared fluorescent nanoprobes for cancer 
molecular imaging: status and challenges. Trends Mol. Med. 16, 574–583. 
doi:10.1016/j.molmed.2010.08.006 
Hilderbrand, S.A., Weissleder, R., 2010. Near-infrared fluorescence: application to in vivo 
molecular imaging. Curr. Opin. Chem. Biol. 14, 71–79. doi:10.1016/j.cbpa.2009.09.029 
ICH guideline Q2(R1) : Validation of Analytical Procedures : Text and Methodology, 2005. 
Jacquart, A., Kéramidas, M., Vollaire, J., Boisgard, R., Pottier, G., Rustique, E., Mittler, F., 
Navarro, F.P., Boutet, J., Coll, J.-L., Texier, I., 2013. LipImageTM 815: Novel dye-loaded lipid 
nanoparticles for long-term and sensitive in vivo near-infrared fluorescence imaging. J. 
Biomed. Opt. 18. doi:10.1117/1.JBO.18.10.101311 
Jiang, C., Cheng, H., Yuan, A., Tang, X., Wu, J., Hu, Y., 2015. Hydrophobic IR780 encapsulated 
in biodegradable human serum albumin nanoparticles for photothermal and photodynamic 
 27 
therapy. Acta Biomater. 14, 61–69. doi:10.1016/j.actbio.2014.11.041 
Keereweer, S., Kerrebijn, J.D.F., van Driel, P.B.A.A., Xie, B., Kaijzel, E.L., Snoeks, T.J.A., Que, 
I., Hutteman, M., van der Vorst, J.R., Mieog, J.S.D., Vahrmeijer, A.L., van de Velde, C.J.H., 
Baatenburg de Jong, R.J., Löwik, C.W.G.M., 2011. Optical image-guided surgery--where do 
we stand? Mol. Imaging Biol. MIB Off. Publ. Acad. Mol. Imaging 13, 199–207. 
doi:10.1007/s11307-010-0373-2 
Khullar, O., Frangioni, J.V., Grinstaff, M., Colson, Y.L., 2009. Image-guided sentinel lymph node 
mapping and nanotechnology-based nodal treatment in lung cancer using invisible near-
infrared fluorescent light. Semin. Thorac. Cardiovasc. Surg. 21, 309–315. 
doi:10.1053/j.semtcvs.2009.11.009 
Kumar, M., Sharma, G., Singla, D., Singh, S., Sahwney, S., Chauhan, A.S., Singh, G., Kaur, I.P., 
2014. Development of a validated UPLC method for simultaneous estimation of both free and 
entrapped (in solid lipid nanoparticles) all-trans retinoic acid and cholecalciferol (vitamin D3) 
and its pharmacokinetic applicability in rats. J. Pharm. Biomed. Anal. 91, 73–80. 
doi:10.1016/j.jpba.2013.12.011 
Lainé, A.-L., Gravier, J., Henry, M., Sancey, L., Béjaud, J., Pancani, E., Wiber, M., Texier, I., 
Coll, J.-L., Benoit, J.-P., Passirani, C., 2014. Conventional versus stealth lipid nanoparticles: 
Formulation and in vivo fate prediction through FRET monitoring. J. Controlled Release 188, 
1–8. doi:10.1016/j.jconrel.2014.05.042 
Li, Z., Wang, H., Chen, Y., Wang, Y., Li, H., Han, H., Chen, T., Jin, Q., Ji, J., 2016. pH- and NIR 
Light-Responsive Polymeric Prodrug Micelles for Hyperthermia-Assisted Site-Specific 
Chemotherapy to Reverse Drug Resistance in Cancer Treatment. Small 12, 2731–2740. 
doi:10.1002/smll.201600365 
Luo, S., Zhang, E., Su, Y., Cheng, T., Shi, C., 2011. A review of NIR dyes in cancer targeting and 
imaging. Biomaterials 32, 7127–7138. doi:10.1016/j.biomaterials.2011.06.024 
Maeda, H., 2001. The enhanced permeability and retention (EPR) effect in tumor vasculature: the 
key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41, 189 – 
207. doi:10.1016/S0065-2571(00)00013-3 
Mérian, J., Gravier, J., Navarro, F., Texier, I., 2012. Fluorescent Nanoprobes Dedicated to in Vivo 
Imaging: From Preclinical Validations to Clinical Translation. Molecules 17, 5564–5591. 
doi:10.3390/molecules17055564 
 28 
Pais-Silva, C., de Melo-Diogo, D., Correia, I.J., 2017. IR780-loaded TPGS-TOS micelles for 
breast cancer photodynamic therapy. Eur. J. Pharm. Biopharm. 113, 108–117. 
doi:10.1016/j.ejpb.2017.01.002 
Peng, X., Wang, Y., Huang, D., Wang, Y., Shin, H.J., Chen, Z., Spewak, M., Mao, H., Wang, X., 
Wang, Y., Chen, Z. (Georgia), Nie, S., Shin, D.M., 2011. Targeted Delivery of Cisplatin to 
Lung Cancer Using ScFvEGFR-Heparin-Cisplatin Nanoparticles. ACS Nano 5, 9480–9493. 
doi:10.1021/nn202410f 
Priem, B., Tian, C., Tang, J., Zhao, Y., Mulder, W.J.M., 2015. Fluorescent nanoparticles for the 
accurate detection of drug delivery. Expert Opin. Drug Deliv. 12, 1881–1894. 
doi:10.1517/17425247.2015.1074567 
Santra, S., Dutta, D., Walter, G.A., Moudgil, B.M., 2005. Fluorescent Nanoparticle Probes for 
Cancer Imaging. Technol. Cancer Res. Treat. 4, 593–602. doi:10.1177/153303460500400603 
Sayag, D., Cabon, Q., Texier, I., Navarro, F.P., Boisgard, R., Virieux-Watrelot, D., Carozzo, C., 
Ponce, F., 2016. Phase-0/phase-I study of dye-loaded lipid nanoparticles for near-infrared 
fluorescence imaging in healthy dogs. Eur. J. Pharm. Biopharm. 100, 85–93. 
doi:10.1016/j.ejpb.2016.01.001 
Shabir, G., 2004. Step-by-step analytical methods and protocol in the quality system compliance 
industry. J. Valid. Technol. 314–24. 
Shabir, G.A., 2004. A practical approach to validation of HPLC methods under current good 
manufacturing practices. J. Valid. Technol. 10, 210–218. 
Shabir, G.A., 2003. Validation of high-performance liquid chromatography methods for 
pharmaceutical analysis. Understanding the differences and similarities between validation 
requirements of the US Food and Drug Administration, the US Pharmacopeia and the 
International Conference on Harmonization. J. Chromatogr. A 987, 57–66. 
Shabir, G.A., Lough, W.J., Arain, S.A., Bradshaw, T.K., 2007. Evaluation and Application of Best 
Practice in Analytical Method Validation. J. Liq. Chromatogr. Relat. Technol. 30, 311–333. 
doi:10.1080/10826070601084753 
Shimizu, Y., Temma, T., Hara, I., Makino, A., Yamahara, R., Ozeki, E., Ono, M., Saji, H., 2014. 
Micelle-based activatable probe for in vivo near-infrared optical imaging of cancer 
biomolecules. Nanomedicine Nanotechnol. Biol. Med. 10, 187–195. 
doi:10.1016/j.nano.2013.06.009 
 29 
Smith, A.M., Mancini, M.C., Nie, S., 2009. Bioimaging: Second window for in vivo imaging. Nat. 
Nanotechnol. 4, 710–711. doi:10.1038/nnano.2009.326 
Sonnergaard, J.M., 2006. On the misinterpretation of the correlation coefficient in pharmaceutical 
sciences. Int. J. Pharm. 321, 12–17. doi:10.1016/j.ijpharm.2006.06.001 
Su, X., Cheng, K., Wang, C., Xing, L., Wu, H., Cheng, Z., 2013. Image-guided resection of 
malignant gliomas using ﬂuorescent nanoparticles. Wiley Interdiscip. Rev. Nanomed. 
Nanobiotechnol. 5, 219–232. doi:10.1002/wnan.1212 
Tan, X., Luo, S., Wang, D., Su, Y., Cheng, T., Shi, C., 2012. A NIR heptamethine dye with 
intrinsic cancer targeting, imaging and photosensitizing properties. Biomaterials 33, 2230–
2239. doi:10.1016/j.biomaterials.2011.11.081 
Troyan, S.L., Kianzad, V., Gibbs-Strauss, S.L., Gioux, S., Matsui, A., Oketokoun, R., Ngo, L., 
Khamene, A., Azar, F., Frangioni, J.V., 2009. The FLARETM Intraoperative Near-Infrared 
Fluorescence Imaging System: A First-in-Human Clinical Trial in Breast Cancer Sentinel 
Lymph Node Mapping. Ann. Surg. Oncol. 16, 2943–2952. doi:10.1245/s10434-009-0594-2 
van der Vorst, J.R., Schaafsma, B.E., Verbeek, F.P.R., Swijnenburg, R.J., Hutteman, M., Liefers, 
G.J., van de Velde, C.J.H., Frangioni, J.V., Vahrmeijer, A.L., 2013. Dose optimization for 
near-infrared fluorescence sentinel lymph node mapping in patients with melanoma. Br. J. 
Dermatol. 168, 93–98. doi:10.1111/bjd.12059 
van Driel, P.B. a. A., van der Vorst, J.R., Verbeek, F.P.R., Oliveira, S., Snoeks, T.J.A., Keereweer, 
S., Chan, B., Boonstra, M.C., Frangioni, J.V., van Bergen en Henegouwen, P.M.P., 
Vahrmeijer, A.L., Lowik, C.W.G.M., 2014. Intraoperative fluorescence delineation of head 
and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody. Int. J. 
Cancer 134, 2663–2673. doi:10.1002/ijc.28601 
Varache, M., Ciancone, M., Caputo, F., Laffont, C., Escudé, M., Jary, D., Boisseau, P., Texier, I., 
Navarro, F., Couffin, A.-C., 2016. Development and validation of characterization methods 
for lipidots® multifunctional platform: A step towards industrial transfer. Adv. Mater. - 
TechConnect Briefs 2016 1, 29–32. 
West, W., Pearce, S., 1965. The Dimeric State of Cyanine Dyes. J. Phys. Chem. 69, 1894–1903. 
doi:10.1021/j100890a019 
Wittenberg, N.J., Haynes, C.L., 2009. Using nanoparticles to push the limits of detection. Wiley 
Interdiscip. Rev. Nanomed. Nanobiotechnol. 1, 237–254. doi:10.1002/wnan.19 
 30 
Wolfbeis, O.S., 2015. An overview of nanoparticles commonly used in fluorescent bioimaging. 
Chem. Soc. Rev. 44, 4743–4768. doi:10.1039/c4cs00392f 
Yi, X., Wang, F., Qin, W., Yang, X., Yuan, J., 2014. Near-infrared fluorescent probes in cancer 
imaging and therapy: an emerging field. Int. J. Nanomedicine 9, 1347–1365. 
doi:10.2147/IJN.S60206 
Yuan, A., Qiu, X., Tang, X., Liu, W., Wu, J., Hu, Y., 2015. Self-assembled PEG-IR-780-C13 
micelle as a targeting, safe and highly-effective photothermal agent for in vivo imaging and 
cancer therapy. Biomaterials 51, 184–193. doi:10.1016/j.biomaterials.2015.01.069 
Yuan, L., Lin, W., Zheng, K., He, L., Huang, W., 2013. Far-red to near infrared analyte-responsive 
fluorescent probes based on organic fluorophore platforms for fluorescence imaging. Chem. 
Soc. Rev. 42, 622–661. doi:10.1039/C2CS35313J 
Yue, C., Liu, P., Zheng, M., Zhao, P., Wang, Y., Ma, Y., Cai, L., 2013. IR-780 dye loaded tumor 
targeting theranostic nanoparticles for NIR imaging and photothermal therapy. Biomaterials 
34, 6853–6861. doi:10.1016/j.biomaterials.2013.05.071 
Zhang, C., Liu, T., Su, Y., Luo, S., Zhu, Y., Tan, X., Fan, S., Zhang, L., Zhou, Y., Cheng, T., Shi, 
C., 2010a. A near-infrared fluorescent heptamethine indocyanine dye with preferential tumor 
accumulation for in vivo imaging. Biomaterials 31, 6612–6617. 
doi:10.1016/j.biomaterials.2010.05.007 
Zhang, C., Wang, S., Xiao, J., Tan, X., Zhu, Y., Su, Y., Cheng, T., Shi, C., 2010b. Sentinel lymph 
node mapping by a near-infrared fluorescent heptamethine dye. Biomaterials 31, 1911–1917. 
doi:10.1016/j.biomaterials.2009.11.061 
Zhegalova, N.G., He, S., Zhou, H., Kim, D.M., Berezin, M.Y., 2014. Minimization of self-
quenching fluorescence on dyes conjugated to biomolecules with multiple labeling sites via 
asymmetrically charged NIR fluorophores. Contrast Media Mol. Imaging 9, 355–362. 
doi:10.1002/cmmi.1585 
 
(a)
(b)
Phospholipids (lecithin)
~
5
0
 n
m
PEG-stearate
co-surfactants
Lipid core
(soyabean oil and wax)
Fluorescent modiﬁed 
Cyanine : IR780-Oleyl (IRO)
N
N+
S
N
H
O
I-
IR780-Oleyl (IRO)
Figure 1
00.5
1
1.5
2
7 7.5 8 8.5 9
F
lu
o
re
sc
en
ce
 s
ig
n
a
l 
(a
rb
. 
u
.)
Time (min)
Figure 2
0 5 10 15 20
F
lu
o
re
sc
en
ce
 s
ig
n
a
l 
(a
rb
. 
u
.)
Time (min)
7 7.5 8 8.5 9
Time (min)
A 
B 
C 
D 
A 
B 
C 
D 
a) b) 
Figure 3
(b)
mean 
+5% 
-5% 
(a)
3 10
4
4 10
4
5 10
4
6 10
4
7 10
4
8 10
4
9 10
4
1 10
5
1.1 10
5
2 3 4 5 6 7 8 9
y = 5458.7 + 12199x   R
2
= 0.9998 
P
ea
k
 a
re
a
Concentration (µg/mL)
1 10
4
1.1 10
4
1.2 10
4
1.3 10
4
1.4 10
4
1.5 10
4
1.6 10
4
0.4 0.5 0.6 0.7 0.8 0.9 1
R
es
p
o
n
se
 f
a
ct
o
r
Log concentration (µg/mL)
Figure 4
00.2
0.4
0.6
0.8
1
1.2
1.4
0 0.2 0.4 0.6 0.8 1 1.2 1.4
0 80 160 240 320 400 480 560
E
x
p
er
im
en
ta
l 
d
y
e 
lo
a
d
in
g
 (
%
)
Theoritical dye loading (%)
Theoritical number of IR780-Oleyl molecules per nanoparticleFigure 5
010
20
30
40
50
60
70
0
0.05
0.1
0.15
0.2
22.03 45.36 91.38 183.2 305.8 362.5 475.6
Z-average diameter PDI
M
ea
n
 h
y
d
ro
d
y
n
a
m
ic
 d
ia
m
et
er
 (
n
m
)
P
o
ly
d
isp
ersity
 in
d
ex
 (P
D
I)
Experimental number of IR780-Oleyl molecules per nanoparticle
Figure 6
1 10
4
1.5 10
4
2 10
4
2.5 10
4
3 10
4
3.5 10
4
4 10
4
4.5 10
4
5 10
4
0 100 200 300 400 500
Intensity per sample 
Intensity per condition
N
o
rm
a
li
ze
d
 f
lu
o
re
sc
en
ce
 i
n
te
n
si
ty
 (
a
rb
. 
u
.)
 
 Experimental number of IR780-Oleyl molecules per nanoparticle
Figure 7
1 10
4
1.5 10
4
2 10
4
2.5 10
4
3 10
4
3.5 10
4
4 10
4
4.5 10
4
5 10
4
0 200 400 600 800 1000 1200
Intensity per condition
Intensity per sample
N
o
rm
a
li
ze
d
 f
lu
o
re
sc
en
ce
 i
n
te
n
si
ty
 (
a
rb
. 
u
.)
 
[Lipids] (µg/mL)
22 dyes/particle 
91 dyes/particle 
363 dyes/particle 
183 dyes/particle 
Figure 8
